紅杉Sofinnova持續加持的“生長髮育第一股”維昇藥業今天上市
維昇藥業(2561.HK)將於3月21日掛牌上市,發行價格爲每股68.80港幣。招股期截止時,維昇藥業公開發售部分預計獲得逾70倍超額認購,國際發售部分同時獲得超額申購。維昇藥業全面行使發行規模調整選擇權後發行規模將擴大15%,發行股數增至1140萬股,公司基礎融資規模達1億美元(含擴大發行規模15%),綠鞋規模1500萬美元(基礎發行規模的15%),是香港市場有史以來首家在醫療健康IPO中引入並全面擴大規模調整選擇權的公司。公司此次IPO引入了5名基石投資者,包括安科生物、蘇州工業園區產業投資基金、Vivo Capital、藥明生物、Reynold Lemkins等。據悉,創始股東維梧資本、Sofinnova、紅杉中國更是持續加碼。這就意味着,維昇藥業將成爲2025年第一家登陸港交所的創新藥企,也將成爲港股“生長髮育第一股”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.